Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
暂无分享,去创建一个
Kwok-Kin Wong | Takeshi Shimamura | P. Jänne | Kwok-Kin Wong | J. Engelman | G. Shapiro | T. Shimamura | R. Padera | Chunxiao Xu | H. Ebi | D. Ercan | Dalia Ercan | Pasi A Jänne | Lu Xu | Hiromichi Ebi | Jeffrey A Engelman | E. Kikuchi | Robert Padera | Geoffrey I Shapiro | Eiki Kikuchi | Chunxiao Xu | Katherine A. Cheng | Katherine A Cheng | Lu Xu | Kwok-kin Wong
[1] E. Rosen,et al. The Multisubstrate Adapter Gab1 Regulates Hepatocyte Growth Factor (Scatter Factor)–c-Met Signaling for Cell Survival and DNA Repair , 2001, Molecular and Cellular Biology.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] M. Ladanyi,et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.
[4] A. Iafrate,et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[6] H. Varmus,et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.
[7] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[8] William Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[9] P. Jänne,et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. , 2006, The Journal of clinical investigation.
[10] M. Meyerson,et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. , 2008, Cancer research.
[11] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[12] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[13] L. Neckers,et al. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors , 2009, Cell cycle.
[14] A. Lowell,et al. Geldanamycins Chaperone and Are Destabilized following Exposure to Domain Mutations Associate with the Heat Shock Protein 90 Epidermal Growth Factor Receptors Harboring Kinase , 2005 .
[15] K. Sugio,et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. , 2010, Lung cancer.
[16] P. Jänne,et al. Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib , 2008, Clinical Cancer Research.
[17] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[18] Kwok-Kin Wong,et al. HKI-272 in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.
[19] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[20] G. Shapiro,et al. Heat shock protein 90 inhibition in lung cancer. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] T. Golub,et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. , 2006, Cancer research.
[22] M. Rivera,et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. , 2007, Cancer research.
[23] T. Mok,et al. Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer , 2009, Pathology & Oncology Research.
[24] M. Meyerson,et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.
[25] H. Ji,et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. , 2007, The Journal of clinical investigation.
[26] M. Meyerson,et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. , 2005, Cancer research.
[27] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[28] J. Whitsett,et al. Conditional expression of genes in the respiratory epithelium in transgenic mice: cautionary notes and toward building a better mouse trap. , 2009, American journal of respiratory cell and molecular biology.
[29] Luca Toschi,et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.
[30] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[31] M. Meyerson,et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[32] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[33] D. Burstein,et al. Perfusion MRI of U87 brain tumors in a mouse model , 2004, Magnetic resonance in medicine.
[34] M. Meyerson,et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. , 2007, Cancer cell.
[35] Susan Quinn,et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Saegusa,et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance , 2008, International journal of cancer.
[37] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[38] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.
[39] M. Socinski,et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Ladanyi,et al. Predictive Biomarkers and Personalized Medicine Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T 790 M Mutation Using a Locked Nucleic Acid-Based Assay , 2011 .
[41] P. Jänne,et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.